OSI Systems, NVE, Biodexa Pharmaceuticals, Clene, Virpax Pharmaceuticals, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are equity shares in companies that research, develop or commercialize products and processes at the nanoscale (typically 1–100 nanometers). These firms apply molecular‐level engineering to fields such as electronics, medicine, materials science and energy. Investors in nanotechnology stocks seek exposure to potentially high‐growth innovations, though they also face elevated technical, regulatory and market risks. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.
OSI Systems (OSIS)
OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.
Shares of NASDAQ:OSIS traded down $2.61 during trading on Friday, hitting $217.58. 68,936 shares of the company's stock were exchanged, compared to its average volume of 194,134. OSI Systems has a 1-year low of $129.18 and a 1-year high of $234.59. The firm has a 50-day moving average price of $206.11 and a two-hundred day moving average price of $190.67. The company has a current ratio of 1.88, a quick ratio of 1.25 and a debt-to-equity ratio of 0.56. The firm has a market cap of $3.65 billion, a P/E ratio of 27.99, a PEG ratio of 1.81 and a beta of 1.28.
Read Our Latest Research Report on OSIS
NVE (NVEC)
NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.
NVEC traded down $0.65 during trading on Friday, reaching $72.43. 59,773 shares of the company's stock were exchanged, compared to its average volume of 23,219. NVE has a fifty-two week low of $51.50 and a fifty-two week high of $89.98. The company's fifty day moving average price is $63.30 and its 200-day moving average price is $70.96. The firm has a market capitalization of $350.34 million, a PE ratio of 23.36 and a beta of 1.09.
Read Our Latest Research Report on NVEC
Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
NASDAQ BDRX traded up $0.01 during trading on Friday, reaching $1.07. 346,726 shares of the stock traded hands, compared to its average volume of 840,780. Biodexa Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $41.50. The stock's 50-day moving average price is $1.40 and its 200 day moving average price is $3.13.
Read Our Latest Research Report on BDRX
Clene (CLNN)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
NASDAQ:CLNN traded up $0.32 on Friday, reaching $3.06. The company's stock had a trading volume of 89,960 shares, compared to its average volume of 81,730. The firm has a market cap of $27.52 million, a PE ratio of -0.57 and a beta of 0.46. Clene has a 1-year low of $2.28 and a 1-year high of $9.20. The business's 50-day moving average price is $2.86 and its two-hundred day moving average price is $4.01.
Read Our Latest Research Report on CLNN
Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Shares of Virpax Pharmaceuticals stock traded up $0.01 on Friday, hitting $0.25. The company had a trading volume of 3,011 shares, compared to its average volume of 201,369. Virpax Pharmaceuticals has a twelve month low of $0.13 and a twelve month high of $84.75. The stock has a 50-day moving average of $0.42 and a 200-day moving average of $5.60.
Read Our Latest Research Report on VRPX
Clene (CLNNW)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Shares of CLNNW stock traded up $0.00 on Friday, hitting $0.03. 4,000 shares of the stock were exchanged, compared to its average volume of 10,744. The business has a 50-day moving average of $0.03 and a 200 day moving average of $0.04. Clene has a fifty-two week low of $0.02 and a fifty-two week high of $0.08.
Read Our Latest Research Report on CLNNW
See Also
Before you consider OSI Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OSI Systems wasn't on the list.
While OSI Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
